New pathologic classification of lung cancer: Relevance for clinical practice and clinical trials

Journal of Clinical Oncology

Volumn 31, Issue 8, 2013, Pages 992-1001

  Travis, William D ^a   Brambilla, Elisabeth ^b   Riely, Gregory J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HÔPITAL MICHALLON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; GEMCITABINE;

ADVANCED CANCER; CANCER CYTODIAGNOSIS; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; GENE MUTATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; INVASIVE MUCINOUS ADENOCARCINOMA; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDICAL SPECIALIST; MINIMALLY INVASIVE ADENOCARCINOMA; MOLECULAR DIAGNOSIS; MORPHOLOGY; NOMENCLATURE; PATHOLOGIST; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ROLE PLAYING; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY;

BIOPSY; CLINICAL TRIALS AS TOPIC; CYTODIAGNOSIS; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; TERMINOLOGY AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84875925170     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.9270     Document Type: Review

References (68)

1. Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thoracic Oncol 6:244-285, 2011
2. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010
3. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-smallcell lung cancer harbouring mutations of the epidermalgrowth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2010
4. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
5. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
6. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735-742, 2011
7. Sasaki T, Janne PA: New strategies for treatment of ALK-rearranged non-small cell lung cancers. Clin Cancer Res 17:7213-7218, 2011
8. Shaw AT, Solomon B: Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 17:2081-2086, 2011
9. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
10. Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 374:1432-1440, 2009
11. Scagliotti G, Hanna N, Fossella F, et al: The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies. Oncologist 14:253-263, 2009
12. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
13. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004 (Pubitemid 41095154)
14. Goozner M: Drug approvals 2011: Focus on companion diagnostics. J Natl Cancer Inst 104:84-86, 2012
15. Yoshida A, Tsuta K, Nakamura H, et al: Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 35:1226-1234, 2011
16. Jokoji R, Yamasaki T, Minami S, et al: Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol 63:1066-1070, 2010
17. Mino-Kenudson M, Chirieac LR, Law K, et al: A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 16:1561-1571, 2010
18. Dutt A, Ramos AH, Hammerman PS, et al: Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 6:e20351, 2011
19. Weiss J, Sos ML, Seidel D, et al: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2:62ra93, 2010
20. Cancer Genome Atlas Research Network, Hammerman PS, Hayes DN, et al: Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:519-525, 2012
21. Travis WD, Brambilla E, Noguchi M, et al: Diagnosis of lung cancer in small biopsies and cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med [epub ahead of print on September 12, 2012]
22. Travis WD, Brambilla E, Muller-Hermelink HK, et al: Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France, IARC, 2004
23. Foot NC: The identification of types of pulmonary cancer in cytologic smears. Am J Pathol 28: 963-983, 1952
24. Johnston WW: Cytologic diagnosis of lung cancer: Principles and problems. Pathol Res Pract 181:1-36, 1986 (Pubitemid 16105818)
25. Travis WD, Rekhtman N, Riley GJ, et al: Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: A paradigm shift. J Thorac Oncol 5:411-414, 2010
26. Rekhtman N, Brandt SM, Sigel CS, et al: Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: High accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 6:451-458, 2011
27. Syrigos KN, Vansteenkiste J, Parikh P, et al: Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. Ann Oncol 21:556-561, 2010
28. Ou SH, Zell JA: Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol 4:1202-1211, 2009
29. Hammerman PS, Sos ML, Ramos AH, et al: Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1:78-89, 2011
30. Li AR, Chitale D, Riely GJ, et al: EGFR mutations in lung adenocarcinomas: Clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 10:242-248, 2008 (Pubitemid 351692167)
31. Lim EH, Zhang SL, Li JL, et al: Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage nonsmall cell lung cancer (NSCLC). J Thorac Oncol 4:12-21, 2009
32. Solomon SB, Zakowski MF, Pao W, et al: Core needle lung biopsy specimens: Adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol 194:266-269, 2010
33. Rossi G, Papotti M, Barbareschi M, et al: Morphology and a limited number of immunohistochemical markers may efficiently subtype nonsmall-cell lung cancer. J Clin Oncol 27:e141-e142, 2009
34. Travis WD, Brambilla E, Noguchi M, et al: Diagnosis of lung adenocarcinoma in resected specimens: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Arch Pathol Lab Med [epub ahead of print on September 12, 2012]
35. Bracci PM, Sison J, Hansen H, et al: Cigarette smoking associated with lung adenocarcinoma in situ in a large case-control study (SFBALCS). J Thorac Oncol 7:1352-1360, 2012
36. Yoshizawa A, Motoi N, Riely GJ, et al: Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: Prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 24:653-664, 2011
37. Russell PA, Wainer Z, Wright GM, et al: Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 6:1496-1504, 2011
38. Yoshizawa A, Sumiyoshi S, Sonobe M, et al: Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: Analysis of 440 Japanese patients. J Thorac Oncol 8:52-61, 2013
39. Warth A, Muley T, Meister M, et al: The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 30:1438-1446, 2012
40. Xu L, Tavora F, Battafarano R, et al: Adenocarcinomas with prominent lepidic spread: Retrospective review applying new classification of the American Thoracic Society. Am J Surg Pathol 36: 273-282, 2012
41. Borczuk AC, Qian F, Kazeros A, et al: Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol 33:462-469, 2009
42. Yim J, Zhu LC, Chiriboga L, et al: Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol 20:233-241, 2007 (Pubitemid 46422178)
43. Maeshima AM, Tochigi N, Yoshida A, et al: Histological scoring for small lung adenocarcinomas 2 cm or less in diameter: A reliable prognostic indicator. J Thorac Oncol 5:333-339, 2010
44. Sica G, Yoshizawa A, Sima CS, et al: A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 34:1155-1162, 2010
45. Kadota K, Suzuki K, Kachala SS, et al: A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol 25:1117-1127, 2012
46. Thunnissen FB, Beasley MB, Borczuk A, et al: Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma: An international interobserver study. Mod Pathol 25:1574-1583, 2012
47. Warth A, Stenzinger A, von Brunneck AC, et al: Interobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary adenocarcinomas. Eur Respir J 40:1221-1227, 2012
48. Warth A, Cortis J, Fink L, et al: Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification. Virchows Arch 461:185-193, 2012
49. Shim HS, Lee da H, Park EJ, et al: Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med 135:1329-1334, 2011
50. Sterlacci W, Savic S, Schmid T, et al: Tissuesparing application of the newly proposed IASLCATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact. Am J Clin Pathol 137:946-956, 2012
51. Awaya H, Takeshima Y, Yamasaki M, et al: Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am J Clin Pathol 121:644-653, 2004 (Pubitemid 38533996)
52. Casali C, Rossi G, Marchioni A, et al: A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: Clinicopathologic analysis, molecular features, and possible pitfalls in routine practice. J Thorac Oncol 5:830-836, 2010
53. Copin MC, Buisine MP, Leteurtre E, et al: Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas. Hum Pathol 32:274-281, 2001 (Pubitemid 32246800)
54. Finberg KE, Sequist LV, Joshi VA, et al: Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 9:320-326, 2007 (Pubitemid 47305068)
55. Garfield DH, Cadranel J, West HL: Bronchioloalveolar carcinoma: The case for two diseases. Clin Lung Cancer 9:24-29, 2008 (Pubitemid 351251597)
56. Hata A, Katakami N, Fujita S, et al: Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. J Thorac Oncol 5:1197-1200, 2010
57. Lee HY, Lee KS, Han J, et al: Mucinous versus nonmucinous solitary pulmonary nodular bronchioloalveolar carcinoma: CT and FDG PET findings and pathologic comparisons. Lung Cancer 65:170-175, 2009
58. Miyake H, Matsumoto A, Terada A, et al: Mucin-producing tumor of the lung: CT findings. J Thorac Imaging 10:96-98, 1995
59. Sato K, Ueda Y, Shikata H, et al: Bronchioloalveolar carcinoma of mixed mucinous and nonmucinous type: Immunohistochemical studies and mutation analysis of the p53 gene. Pathol Res Pract 202:751-756, 2006 (Pubitemid 44362200)
60. Wislez M, Antoine M, Baudrin L, et al: Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer 68:185-191, 2010
61. Inamura K, Takeuchi K, Togashi Y, et al: EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3:13-17, 2008
62. Yoshida A, Tsuta K, Watanabe S, et al: Frequent ALK rearrangement and TTF-1/p63 coexpression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 72:309-315, 2010
63. McLeer-Florin A, Moro-Sibilot D, Melis A, et al: Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: A French study. J Thorac Oncol 7:348-354, 2011
64. Girard N, Ostrovnaya I, Lau C, et al: Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res 15:5184-5190, 2009
65. Girard N, Deshpande C, Lau C, et al: Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 33:1752-1764, 2009
66. Finley DJ, Yoshizawa A, Travis W, et al: Predictors of outcomes after surgical treatment of synchronous primary lung cancers. J Thorac Oncol 5:197-205, 2010
67. Bhure UN, Lardinois D, Kalff V, et al: Accuracy of CT parameters for assessment of tumour size and aggressiveness in lung adenocarcinoma with bronchoalveolar elements. Br J Radiol 83:841-849, 2010
68. Lee HY, Han J, Lee KS, et al: Lung adenocarcinoma as a solitary pulmonary nodule: Prognostic determinants of CT, PET, and histopathologic findings. Lung Cancer 66:379-385, 2009